Laidlaw lowered the firm’s price target on Beyond Air (XAIR) to $5 from $8 and keeps a Buy rating on the shares following the fiscal Q2 report. The firm says Beyond Air is at the early execution stage of LungFit PH commercialization by the new commercial team. It expects more significant sales starting in 2025.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter